Back to search results

PARADISE Registry for Prostate Ablation

The PARADISE study is an observational registry for men with prostate cancer who are undergoing or have undergone prostate ablation. Prostate ablation is a procedure that destroys prostate cancer cells in a minimally invasive way. This study aims to collect information on how well prostate ablation works and its effects over time. Researchers will track your PSA (Prostate Specific Antigen, a blood test for prostate health) levels, biopsy results, and other health markers for up to 10 years. This study is open to men aged 22 or older with a prostate cancer diagnosis who are having or have had prostate ablation using various energy sources like cryotherapy or laser.

Study design
This is an observational study planning to enroll 3000 participants. It is not testing a new treatment but rather collecting information on an existing procedure.
What's involved
You would have follow-up visits every 6 months for 2 years, then annually for up to 10 years. During these visits, your PSA levels, biopsy results, and other health markers will be checked.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 10 years after their prostate cancer management.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06705803

Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)

Recruiting
Not specifiedAges 22+Observational
University of Chicago
~3,000 participants
Updated 2026-02-02 on ClinicalTrials.gov
What's tested:Prostate Ablation

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with descriptive summarization of Prostate specific antigen (PSA) and its derivatives to represent clinicopathologic, interventions, and oncological outcomes
Measured over Follow up every 6 months (at minimum) for 2 years, and annually through 10 years of total follow-up after prostate cancer management.
+7 more outcomes measured

Conditions

Prostate Cancer

Explore related trials

Prostate Carcinoma

Where it's being run

2 sites across 2 states
Illinois1
Ohio1

Study leadership

  • Abhinav Sidana, MD · PRINCIPAL_INVESTIGATOR · University of Chicago

Who to contact

Abhinav Sidana, MD
[email protected]
773-834-5087
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male sex
≥22 years of age
Histologic diagnosis of prostate cancer
Scheduled to undergo or have already undergone ablation of the prostate as part of routine clinical care or any ongoing clinical trials
Prostate ablation performed with any of the following energy sources: cryotherapy, high-intensity focused ultrasound, irreversible electroporation, laser, microwave, radiofrequency ablation, or photodynamic therapy. Newer methods and instrumentation continue to be developed to ablate tissue, and these energy sources can be entered into the registry as clinical use begins

Exclusion

Under 21 Years of age.

What this trial measures

  • Number of Participants with descriptive summarization of Prostate specific antigen (PSA) and its derivatives to represent clinicopathologic, interventions, and oncological outcomesFollow up every 6 months (at minimum) for 2 years, and annually through 10 years of total follow-up after prostate cancer management.

    Descriptive summarization of Prostate specific antigen (PSA) and its derivatives

  • Number of Participants with descriptive summarization of prostate biopsyFollow up every 6 months (at minimum) for 2 years, and annually through 10 years of total follow-up after prostate cancer management.

    Descriptive summarization of prostate biopsy to represent clinicopathologic, interventions, and oncological outcomes

  • Number of Participants with descriptive summarization of biomarkersFollow up every 6 months (at minimum) for 2 years, and annually through 10 years of total follow-up after prostate cancer management.

    Descriptive summarization of biomarkers to represent clinicopathologic, interventions, and oncological outcomes

  • Number of Participants with descriptive summarization of imaging findingsFollow up every 6 months (at minimum) for 2 years, and annually through 10 years of total follow-up after prostate cancer management.

    Descriptive summarization of imaging findings to represent clinicopathologic, interventions, and oncological outcomes

  • Number of Participants with descriptive summarization of urination functionFollow up every 6 months (at minimum) for 2 years, and annually through 10 years of total follow-up after prostate cancer management.

    Descriptive summarization of urination function to represent clinicopathologic, interventions, and genitourinary functional outcomes

  • Number of Participants with descriptive summarization of bowel functionFollow up every 6 months (at minimum) for 2 years, and annually through 10 years of total follow-up after prostate cancer management.

    Descriptive summarization of bowel function to represent clinicopathologic, interventions, and genitourinary functional outcomes

  • Number of Participants with descriptive summarization of sexual functionFollow up every 6 months (at minimum) for 2 years, and annually through 10 years of total follow-up after prostate cancer management.

    Descriptive summarization of sexual function to represent clinicopathologic, interventions, and genitourinary functional outcomes

  • Number of Participants with descriptive summarization of the overall quality of life parametersFollow up every 6 months (at minimum) for 2 years, and annually through 10 years of total follow-up after prostate cancer management.

    Descriptive summarization of the overall quality of life parameters to represent clinicopathologic, interventions, and genitourinary functional outcomes